The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-15 and is reviewed periodically as new material appears.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
=== In film === Several movies deal with rabies vaccine, notably the 1936 The Story of Louis Pasteur, which focuses on the life and achievements of Louis Pasteur, played by Paul Muni. The 1966 film Rage features a man bitten by a rabid dog who engages in a race against time to reach the nearest medical establishment to get the vaccine.
There has been a tremendous advance in speed and cost reduction since the completion of the Human Genome Project, with some labs able to sequence over 100,000 billion bases each year, and a full genome can be sequenced for $1,000 or less. Computers became essential in molecular biology when protein sequences became available after Frederick Sanger determined the sequence of insulin in the early 1950s. Comparing multiple sequences manually turned out to be impractical. Margaret Oakley Dayhoff, a pioneer in the field, compiled one of the first protein sequence databases, initially published as books as well as methods of sequence alignment and molecular evolution. Another early contributor to bioinformatics was Elvin A. Kabat, who pioneered biological sequence analysis in 1970 with his comprehensive volumes of antibody sequences released online with Tai Te Wu between 1980 and 1991. In the 1970s, new techniques for sequencing DNA were applied to bacteriophage MS2 and øX174, and the extended nucleotide sequences were then parsed with informational and statistical algorithms. These studies showed that well-known features, such as coding segments and the triplet code, could be revealed in straightforward statistical analyses and were proof of the concept that bioinformatics would be insightful.
In physical chemistry and fluid mechanics, a non-Newtonian fluid is a fluid that does not follow Newton's law of viscosity; that is, it has variable viscosity dependent on stress. In particular, the viscosity of non-Newtonian fluids can change when subjected to force. Ketchup, for example, becomes runnier when shaken and is thus a non-Newtonian fluid. Many salt solutions and molten polymers are non-Newtonian fluids, as are many commonly found substances such as custard, toothpaste, starch suspensions, paint, blood, melted butter and shampoo. A common demonstration of non-Newtonian fluids involves so-called "Ooblek" (), a mixture of corn or potato starch and water. It demonstrates shear thickening. With slow motions it is a moderately viscous fluid, increases in viscosity as disturbed, and briefly transforms into a near solid mass upon a sudden impact. Most commonly, the viscosity (the gradual deformation by shear or tensile stresses) of non-Newtonian fluids is dependent on shear rate or shear rate history. Some non-Newtonian fluids with shear-independent viscosity, however, still exhibit normal stress-differences or other non-Newtonian behavior. In a Newtonian fluid, the relation between the shear stress and the shear rate is linear, passing through the origin, the constant of proportionality being the coefficient of viscosity. In a non-Newtonian fluid, the relation between the shear stress and the shear rate is different. The fluid can even exhibit time-dependent viscosity. Therefore, a constant coefficient of viscosity cannot be defined.
== Background == Sudden Coffee was founded by Joshua Zloof and Kalle Freese. Freese & Zloof saw the demand to make properly brewed 'specialty coffee' easily available outside of major metropolitan areas. Sudden Coffee was founded with help from advisors Caterina Fake (co-founder of Flickr) and Jyri Engestrom (co-founder of Jaiku). In the winter of 2017, Sudden Coffee became the second food company to be accepted by the Y Combinator accelerator. Sudden Coffee originally started as a monthly subscription service.
=== Aging === Studies in female mice have shown that both supraoptic nucleus (SON) and paraventricular nucleus (PVN) lose approximately one-third of IGF-1R immunoreactive cells with normal aging. Also, old calorically restricted (CR) mice lost higher numbers of IGF-1R non-immunoreactive cells while maintaining similar counts of IGF-1R immunoreactive cells in comparison to old-Al mice. Consequently, old-CR mice show a higher percentage of IGF-1R immunoreactive cells, reflecting increased hypothalamic sensitivity to IGF-1 in comparison to normally aging mice.
Sources: en.wikipedia.org
== Legal Issues == On 2 May 2018, he was charged with seven counts of drug trafficking and possession. He was released on $20,000 bail to appear in court at a later date. He was later cleared of trafficking but convicted of possession.
==== Direct-acting antivirals ==== The term direct-acting antiviral (DAA) was first coined to describe anti-hepatitis C drugs that directly targeted viral processes. Prior antiviral regimens were designed to supplement the immune system's ability to fight infection as a whole. In comparison, DAAs directly disrupt hepatitis C virus entry and replication processes by interfering with viral proteins. Prior to the discovery of DAAs, hepatitis C was treated with a combination of interferon and ribavirin which increase expression of genes involved in the antiviral immune response. DAAs drastically improved treatment outcomes by increasing safety and efficacy through increased specificity, resulting in increased sustained virological response (SVR) rates. SVR is achieved when hepatitis C virus RNA remains undetectable 12–24 weeks after treatment ends. Once SVR is achieved, treatment is considered a success. Combination therapy of interferon and ribavirin has a SVR rate of approximately 65%. In contrast, SVR rates in clinical trials for numerous DAAs can be as high as 95%. The DAA drugs against hepatitis C are taken orally, as tablets, for 8 to 12 weeks and the antiviral prescribed depends on the strain (genotypes) of hepatitis C virus that are causing the infection. Both during and at the end of treatment, blood tests are used to monitor the effectiveness of the treatment and subsequent cure. The DAA commonly used combination drugs used to treat hepatitis C viral infections include:
Suppression of transthyretin production: Until 2018, liver and/or heart transplantation were the only ways to definitively treat TTR amyloidosis. Liver transplantation replaces the liver that is producing abnormal TTR proteins, and a heart transplantation replaces the heart with amyloid deposits for a non-diseased heart. Liver transplantation does not always halt the disease, and in some cases disease progression continues. Medications such as patisiran and inotersen can also decreases the activity of the transthyretin genes. These medications bind to the mRNA of transthyretin and prevent the production of the transthyretin protein, thus decreasing the overall amount of transthyretin that can accumulate in the body. Stabilization of abnormal transthyretin: There are medications that can stabilize the normally folded transthyretin, preventing misfolding and subsequent amyloid deposition. These medications include tafamidis, the non-steroidal anti-inflammatory drug (NSAID) diflunisal, and acoramidis. Tafamidis is a medication that binds to transthyretin and keeps it in its normal shape, stopping it from aggregating into amyloid fibrils. Diflunisal and acoramidis work in a similar manner to tafamidis in their ability to bind to and stabilize transthyretin. In a 30-month trial, tafamidis showed reduced mortality and reduced heart failure related hospitalizations compared to placebo. Tafamidis was also shown to improve functional capacity and quality of life in those with TTR amyloidosis.
== Chemical structure == The chemical structure of sodium stibogluconate is somewhat ambiguous, and the structure shown above is idealized. Its solutions may contain multiple antimony compounds, although this heterogeneity may be unimportant. It has been speculated that the active species contains only a single antimony centre.
In 1795, observing the toll that poor nutrition took on his men, Napoleon announced a prize of 12,000 francs to anyone who could improve upon the prevailing food preservation methods of the time. In 1810, Nicholas Appert claimed the prize after devising a method of preserving food in which tightly sealing food inside a bottle and maintaining it at high temperature for certain period of time made the food safe for consumption until opening, using glass jars sealed with corks and boiling water. A trial in which food preserved by this method was sent overseas with French troops succeeded. Appert was given the money on condition that he make his discovery public, and duly published The Art of Preserving Animal and Vegetable Substances. The French Navy began using his methods. The Grande Armée experimented with issuing canned foods to its soldiers. However, the slow process of canning and the even slower development and transport stages prevented large amounts from being shipped across the French Empire, and the wars ended before the process was perfected. A major difficulty that presented itself was the use of glass, which was heavy, fragile, and could explode under internal pressure. Appert's work was improved upon by Philippe de Girard in 1811, when he pioneered a method of preserving food in metal cans. It was patented in Britain on his behalf by Peter Durand, who took the credit as its inventor. Girard, a Frenchman, preferred the entrepreneurial environment of Britain, but could not have taken out a patent in a country with which his own country was at war with.
Sources: en.wikipedia.org
Jollibee offers American-influenced fast food items and casual Filipino fare. Among the establishment's best sellers are the Yumburger, the house hamburger first introduced during their early days of operation; the Chickenjoy, a fried chicken meal, introduced in the 1980s, with regular and spicy versions; and Jolly Spaghetti, a sweet Filipino spaghetti that includes a beef sauce with pieces of hot dog and ham. In 1995, Jollibee introduced the Burger Steak to its menu. At its international locations, Jollibee also offers localized products, such as chili chicken in Vietnam and nasi lemak in Brunei. Jollibee serves Coca-Cola products in Luzon and Visayas and Pepsi products in Mindanao and its overseas markets.
=== Targeted protein degradation === Based on the finding that thalidomide and related analogues bind CRBN, heterobifunctional molecules were designed linking thalidomide to ligands for other proteins of interest. These molecules, termed proteolysis targeting chimeras (PROTACs) or protein degraders, recruit CRBN to a protein of interest, leading to its ubiquitination and subsequent degradation. This technology is being explored in clinical trials by a number of biotechnology companies such as Arvinas, C4 Therapeutics, and Kymera Therapeutics.
=== Physiological causes === Physiological (i.e., non-pathological) causes that can increase prolactin levels include: ovulation, pregnancy, breastfeeding, chest wall injury, stress, stress-associated REM sleep, and exercise. During pregnancy, prolactin increases can range up to 600 ng/mL, depending on estrogen and progesterone concentrations. After delivery, progesterone concentrations decrease, and prolactin levels drop. Only during nipple stimulation will prolactin levels rise, allowing for milk production. At 6 weeks post-birth (postpartum), estradiol concentrations decrease, and prolactin concentrations return to normal even during breastfeeding. Fluctuations in prolactin levels during menstrual cycles and menopause are inconclusive. Stress-related factors include physical exercise, hypoglycemia, myocardial infarction, and surgery. While aerobic and anaerobic activity increases prolactin, anaerobic activity has a greater effect. Coitus can also contribute to an increased prolactin release. Prolactin serum concentrations increase during nocturnal sleep, and increase transiently during daytime naps. After waking, prolactin levels return to daytime levels within 60–90 minutes.
Federated States of Micronesia - Scouting in the Federated States of Micronesia* - Aloha Council of the Boy Scouts of America Marshall Islands - Scouting in the Marshall Islands* - Aloha Council of the Boy Scouts of America Palau - Scouting in Palau* - Aloha Council of the Boy Scouts of America Served by The Scout Association (UK)
The underconnectivity theory of autism posits that autistic people tend to have fewer high-level neural connections and less global synchronization, along with an excess of low-level processes. Functional connectivity studies have found both hypo- and hyperconnectivity in brains of autistic people. Hypoconnectivity is commonly observed for interhemispheric (e.g. lower neuron density in corpus callosum) and cortico-cortical functional connectivity. Some studies have found local overconnectivity in the cerebral cortex and weak functional connections between the frontal lobe and the rest of the cortex. Abnormal default mode network (task-negative) connectivity is often observed. Toggling between task-negative network activation and task-positive network activation (consisting of the dorsal attention network and salience network) may be less efficient, possibly reflecting a disturbance of self-referential thought. Such patterns of low function and aberrant activation in the brain may depend on whether the brain is performing social or nonsocial tasks. Some studies have suggested that autism is a disorder of the association cortex. Event-related potentials with respect to attention, orientation to auditory and visual stimuli, novelty detection, language and face processing, and information storage are altered in autistic individuals; several studies have found a preference for nonsocial stimuli. Magnetoencephalography studies have observed delayed processing of auditory signals in autistic children.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.